X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1501) 1501
Publication (205) 205
Book Review (31) 31
Newsletter (17) 17
Book Chapter (3) 3
Magazine Article (2) 2
Conference Proceeding (1) 1
Dissertation (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (951) 951
indinavir (734) 734
pharmacology & pharmacy (659) 659
male (462) 462
hiv infections - drug therapy (458) 458
hiv protease inhibitors - pharmacology (369) 369
adult (361) 361
female (357) 357
indinavir - pharmacology (326) 326
protease inhibitors (276) 276
ritonavir (258) 258
infectious diseases (252) 252
hiv (242) 242
hiv protease inhibitors - therapeutic use (217) 217
middle aged (216) 216
hiv-1 - drug effects (214) 214
animals (209) 209
drug therapy, combination (207) 207
hiv protease inhibitors - pharmacokinetics (203) 203
index medicus (203) 203
antiretroviral therapy (196) 196
virology (188) 188
pharmacokinetics (187) 187
anti-hiv agents - therapeutic use (186) 186
saquinavir (177) 177
indinavir - therapeutic use (174) 174
indinavir - pharmacokinetics (170) 170
antiviral agents (168) 168
microbiology (162) 162
therapy (161) 161
hiv infections - virology (159) 159
anti-hiv agents - pharmacology (152) 152
drug interactions (152) 152
indinavir, adverse reactions (151) 151
nelfinavir (150) 150
human-immunodeficiency-virus (147) 147
infection (144) 144
zidovudine (143) 143
ritonavir - pharmacology (139) 139
pharmacology/toxicology (136) 136
hiv protease inhibitors - administration & dosage (123) 123
medicine & public health (120) 120
immunology (116) 116
viral load (115) 115
hiv-1 - genetics (114) 114
hiv protease inhibitors - blood (113) 113
indinavir - administration & dosage (113) 113
saquinavir - pharmacology (113) 113
area under curve (111) 111
hiv protease inhibitors - adverse effects (109) 109
lamivudine (105) 105
lopinavir (104) 104
hiv-1 (103) 103
anti-hiv agents - pharmacokinetics (96) 96
aids (95) 95
anti-hiv agents - administration & dosage (93) 93
indinavir - blood (93) 93
indinavir - adverse effects (91) 91
ritonavir - therapeutic use (90) 90
dose-response relationship, drug (89) 89
cd4 lymphocyte count (88) 88
hiv protease - genetics (88) 88
p-glycoprotein (88) 88
protease inhibitor (87) 87
resistance (87) 87
in-vitro (86) 86
reverse transcriptase inhibitors - therapeutic use (84) 84
mice (83) 83
drug safety and pharmacovigilance (82) 82
drug therapy (82) 82
hiv infection (81) 81
rats (81) 81
hiv infections - metabolism (80) 80
mutation (80) 80
nelfinavir - pharmacology (80) 80
metabolism (79) 79
virus diseases (79) 79
amprenavir (78) 78
biochemistry & molecular biology (76) 76
indinavir, adverse reactions - serious (76) 76
adolescent (75) 75
anti-hiv agents (72) 72
toxicology (72) 72
ritonavir - pharmacokinetics (71) 71
active antiretroviral therapy (70) 70
pharmacology (70) 70
antiretroviral therapy, highly active (69) 69
chromatography, high pressure liquid (69) 69
rna, viral - blood (69) 69
time factors (69) 69
anti-hiv agents - adverse effects (67) 67
hiv protease inhibitors (67) 67
ritonavir - administration & dosage (67) 67
cell line (66) 66
efavirenz (65) 65
highly active antiretroviral therapy (64) 64
research (64) 64
viruses (64) 64
combination (62) 62
treatment outcome (62) 62
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1493) 1493
French (11) 11
Spanish (8) 8
German (4) 4
Italian (3) 3
Portuguese (3) 3
Russian (2) 2
Dutch (1) 1
Japanese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 2017, Volume 12, Issue 7, p. e0181357
Journal Article
Current Topics in Medicinal Chemistry, ISSN 1568-0266, 2004, Volume 4, Issue 10, pp. 1079 - 1095
There are currently (July, 2002) six protease inhibitors approved for the treatment of HIV infection, each of which can be classified as peptidomimetic in... 
CHEMISTRY, MEDICINAL | REVERSE-TRANSCRIPTASE INHIBITORS | ORALLY BIOAVAILABLE INHIBITOR | BIOLOGICAL EVALUATION | ANTIVIRAL ACTIVITY | SOCIETY-USA PANEL | ANTIRETROVIRAL THERAPY | INFECTED PATIENTS | HUMAN-IMMUNODEFICIENCY-VIRUS | TYPE-1 PROTEASE | STRUCTURE-BASED DESIGN | Anti-HIV Agents - pharmacology | Pyridines - chemistry | Humans | Saquinavir - therapeutic use | Urethane - chemistry | Pyrimidinones - chemistry | Oligopeptides - therapeutic use | HIV Protease Inhibitors - pharmacology | Saquinavir - pharmacology | Urethane - therapeutic use | Atazanavir Sulfate | Phenylbutyrates - pharmacology | Ritonavir - therapeutic use | Oligopeptides - chemistry | Saquinavir - chemistry | Lopinavir | Pyrimidinones - therapeutic use | Models, Molecular | Sulfonamides - pharmacology | HIV Protease Inhibitors - therapeutic use | Nelfinavir - pharmacology | Anti-HIV Agents - chemistry | Carbamates | Urethane - pharmacology | Oligopeptides - pharmacology | Organophosphates - therapeutic use | Indinavir - pharmacology | Urethane - analogs & derivatives | HIV - drug effects | Molecular Mimicry | Phenylbutyrates - chemistry | Anti-HIV Agents - therapeutic use | Pyrimidinones - pharmacology | Ritonavir - pharmacology | Molecular Structure | Pyridines - therapeutic use | Nelfinavir - therapeutic use | Peptides - chemistry | Sulfonamides - chemistry | Dipeptides - pharmacology | HIV Protease Inhibitors - chemistry | Clinical Trials as Topic | Dipeptides - chemistry | Ritonavir - chemistry | Peptides - pharmacology | Organophosphates - pharmacology | Sulfonamides - therapeutic use | HIV Infections - drug therapy | Organophosphates - chemistry | Pyridines - pharmacology | Peptides - therapeutic use | Indinavir - therapeutic use
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2011, Volume 11, Issue 10, pp. 769 - 779
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2014, Volume 9, Issue 12, p. e113957
Background: Aspartic peptidase inhibitors have shown antimicrobial action against distinct microorganisms. Due to an increase in the occurrence of Chagas'... 
IN-VITRO | TRYPOMASTIGOTE FORMS | MULTIDISCIPLINARY SCIENCES | DRUGS | CHAGAS-DISEASE | RHODNIUS-PROLIXUS-MIDGUT | INFECTION | LEISHMANIA-AMAZONENSIS | DIFFERENTIATION | PROTEASE INHIBITORS | CELL-DEATH | Anti-HIV Agents - pharmacology | Microscopy, Electron, Transmission | Lopinavir - pharmacology | Indinavir - pharmacology | Sulfonamides - pharmacology | Aspartic Acid Proteases - metabolism | Nelfinavir - pharmacology | Saquinavir - pharmacology | Host-Parasite Interactions - drug effects | Protease Inhibitors - pharmacology | Animals | Trypanosoma cruzi - growth & development | Trypanocidal Agents - pharmacology | Insect Vectors - parasitology | Trypanosoma cruzi - drug effects | Ritonavir - pharmacology | Aspartic Acid Proteases - antagonists & inhibitors | Trypanosoma cruzi - ultrastructure | Carbamates - pharmacology | Infection | Antiviral agents | Calpain | HIV (Viruses) | Health aspects | Flow cytometry | Ritonavir | Immunoblotting | Parasites | Phylogeny | Trypomastigotes | Alterations | Microorganisms | Acquired immune deficiency syndrome--AIDS | Etiology | Human immunodeficiency virus--HIV | Nelfinavir | Cruzipain | Cathepsin D | Pretreatment | Cell body | Vector-borne diseases | Protozoa | Peptidase | Lopinavir | Substrate inhibition | Decoding | Peptidases | Detachment | Transmission electron microscopy | Disease transmission | Inhibitors | Epimastigotes | Chagas' disease | Cell size | Flagella | Viability | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 03/2011, Volume 150, Issue 2, pp. 204 - 211
Long-term antiretroviral therapy (ART) for human immunodeficiency virus type one (HIV-1) infection shows limitations in pharmacokinetics and biodistribution... 
Nanoparticles | HIV | Monocyte | Crystalline | Antiretroviral | Nanomedicine | Macrophage | CELLS | HUMAN-IMMUNODEFICIENCY-VIRUS | CHEMISTRY, MULTIDISCIPLINARY | ANTI-HIV DRUGS | ADHERENCE | DELIVERY | PHYSICOCHEMICAL PROPERTIES | THERAPY | PHARMACOKINETICS | WATER-SOLUBLE DRUGS | PHARMACOLOGY & PHARMACY | Indinavir - administration & dosage | Nanoparticles - chemistry | Humans | Benzoxazines - metabolism | Indinavir - pharmacology | Microbial Sensitivity Tests | Macrophages - virology | Atazanavir Sulfate | Ritonavir - pharmacology | Indinavir - metabolism | Microscopy, Electron, Transmission | Virus Replication - drug effects | Microscopy, Electron, Scanning | Pyridines - administration & dosage | Benzoxazines - administration & dosage | Ritonavir - administration & dosage | HIV-1 - drug effects | Anti-Retroviral Agents - pharmacology | Oligopeptides - metabolism | Static Electricity | Anti-Retroviral Agents - metabolism | Particle Size | Macrophages - metabolism | Pyridines - metabolism | Ritonavir - metabolism | Anti-Retroviral Agents - administration & dosage | Benzoxazines - pharmacology | Macrophages - drug effects | Oligopeptides - administration & dosage | Pyridines - pharmacology | Surface-Active Agents - chemistry | Oligopeptides - pharmacology | Highly active antiretroviral therapy | Antiviral agents | Macrophages | Analysis | Particle size | Surface charge | Ritonavir | antiretroviral therapy | Cytotoxicity | Drug delivery | Coatings | Surfactants | Efavirenz | Infection | Monocytes | nanoparticles | Physical characteristics | Antiviral activity | Replication | Pharmacokinetics | Controlled release | Indinavir | antiretroviral | crystalline | macrophage | monocyte | nanomedicine
Journal Article
Journal of Neurochemistry, ISSN 0022-3042, 01/2012, Volume 120, Issue 1, pp. 78 - 92
Antiretroviral drugs lower the GSH content of cultured astrocytes.Antiretroviral protease inhibitors are used as drugs for the combinatorial therapy of HIV... 
AIDS | transport | HIV | multidrug resistance protein | glutathione | GLUTATHIONE TRANSPORT | OXIDATIVE STRESS | BIOCHEMISTRY & MOLECULAR BIOLOGY | RESISTANCE PROTEIN-1 MRP1 | RAT ASTROCYTES | ASTROGLIAL CELLS | NEUROSCIENCES | HIV-INFECTED PATIENTS | P-GLYCOPROTEIN | IN-VITRO | NEUROCOGNITIVE IMPAIRMENT | EXOGENOUS HYDROGEN-PEROXIDE | Animals, Newborn | Brain Chemistry - drug effects | Hydrogen Peroxide - toxicity | Propionates - pharmacology | Astrocytes - drug effects | Cell Survival - drug effects | Reactive Oxygen Species - metabolism | Rats, Wistar | Glutathione - metabolism | Lactic Acid - metabolism | Cells, Cultured | Indinavir - pharmacology | Rats | Reverse Transcriptase Inhibitors - pharmacology | Quinolines - pharmacology | Nelfinavir - pharmacology | HIV Protease Inhibitors - pharmacology | Animals | Leukotriene Antagonists - pharmacology | Multidrug Resistance-Associated Proteins - physiology | Glucose - metabolism | Oxidative Stress - drug effects | Astrocytes - metabolism | Drug resistance in microorganisms | Usage | Protease inhibitors | Proteases | AIDS (Disease) | Green technology | Immunodeficiency | DNA polymerases | Lamivudine | HIV (Viruses) | Zidovudine | Dementia | Neurochemistry | Antiretroviral drugs | Pharmacology | Drug resistance | Antiviral agents | Brain | Cell culture | RNA-directed DNA polymerase | Nevirapine | Astrocytes | Multidrug resistance | Homeostasis | Data processing | Proteinase inhibitors | Metabolism | Efavirenz | Immunosuppressive agents | Infection | Acquired immune deficiency syndrome | Nelfinavir | Dementia disorders | Protein transport | Indinavir | Glutathione
Journal Article
Antiviral Research, ISSN 0166-3542, 2000, Volume 47, Issue 2, pp. 121 - 129
AIDS therapies employing HIV protease inhibitors (PIs) are associated with changes in fat metabolism. However, the cellular mechanisms affected by PIs are not... 
Lipodystrophy | HIV | Protease inhibitors | Lipolysis | Adipogenesis | MITOCHONDRIAL TOXICITY | COMPLEMENT | ACTIVATED RECEPTOR-GAMMA | DIABETES-MELLITUS | adipogenesis | THERAPY | VIROLOGY | INSULIN-RESISTANCE | protease inhibitors | ADIPOCYTE DIFFERENTIATION | PHARMACOLOGY & PHARMACY | INFECTION | lipolysis | lipodystrophy | ADIPOSE-TISSUE | Fatty Acid-Binding Proteins | Retinoid X Receptors | Lipolysis - drug effects | Coloring Agents - pharmacology | Indinavir - pharmacology | RNA, Messenger - analysis | Adipocytes - cytology | HIV Protease Inhibitors - pharmacology | Saquinavir - pharmacology | Stem Cells | Neoplasm Proteins | Receptors, Retinoic Acid - agonists | Ritonavir - pharmacology | Azo Compounds - pharmacology | Lipoprotein Lipase - metabolism | Insulin - pharmacology | Lipoprotein Lipase - genetics | Cells, Cultured | Receptors, Retinoic Acid - metabolism | Receptors, Cytoplasmic and Nuclear - agonists | Sulfonamides - pharmacology | Nelfinavir - pharmacology | Triglycerides - metabolism | Transcription Factors - metabolism | Carrier Proteins - genetics | Animals | Carrier Proteins - metabolism | Cell Differentiation - drug effects | Tetrahydronaphthalenes - pharmacology | Adipocytes - metabolism | Carbamates | Thiazoles - pharmacology | Transcription Factors - agonists | Thiazolidinediones | Receptors, Cytoplasmic and Nuclear - metabolism
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2013, Volume 8, Issue 6, p. e65994
High mobility group box 1 (HMGB1), a highly conserved, ubiquitous protein, is released into the circulation during sterile inflammation (e. g. arthritis,... 
SYSTEMIC INFLAMMATION | SURVIVAL | TUMOR-NECROSIS-FACTOR | ACTIVATION | MULTIDISCIPLINARY SCIENCES | TRANSCRIPTION | RECEPTOR | KAPPA-B | HMGB1 | CYTOKINE RELEASE | BINDING | Tumor Necrosis Factor-alpha - metabolism | Phosphorylation | Gene Expression - drug effects | Albuterol - pharmacology | MAP Kinase Signaling System | Dexamethasone - pharmacology | HMGB1 Protein - metabolism | Inflammation Mediators - metabolism | Drug Evaluation, Preclinical | HMGB1 Protein - antagonists & inhibitors | Macrophages - immunology | Cell Line | Cell Survival - drug effects | Anti-Inflammatory Agents - pharmacology | Down-Regulation | Adrenergic beta-Agonists - pharmacology | Prednisolone - pharmacology | Drug Synergism | Macrophages - metabolism | Animals | Energy Metabolism | Glucocorticoids - pharmacology | Macrophages - drug effects | Mice | Protein Processing, Post-Translational | Catecholamines - pharmacology | Hostages | Arthritis | Inflammation | Thiols | Corticosteroids | Chromosomal proteins | Drugs | Cell culture | Glucocorticoids | Transcription | Laboratories | Pathogenesis | Science | Inflammatory response | Macrophages | HMGB1 protein | Modulators | Proteins | Salbutamol | Inhibition | Pretreatment | Prednisolone | Indinavir | Library collections | Medical research | Cytokines | Extracellular signal-regulated kinase | Pharmacology | Tumor necrosis factor-α | Trauma | Screening | High mobility group proteins | Brain research | Natural products | TNF inhibitors | Anesthesiology | Binding sites
Journal Article